Loading...
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
Immunotherapy with programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) targeted monoclonal antibodies has dramatically changed the therapeutic and prognostic landscape for several types of malignancy. PD-1 and PD-L1 are immune checkpoint proteins whose binding ultimately result in T cell...
Saved in:
| Published in: | Mol Diagn Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5773410/ https://ncbi.nlm.nih.gov/pubmed/29119407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40291-017-0308-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|